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APPROPRIATE ICU UTILIZATION FOR BMT PATIENTS
Jenkins, T.L. Stanford University Hopsital, Stanford, CA.
Purpose:To develop criteria to ensure appropriate admission of
BMT patients to the ICU. In order to avoid inappropriate ICU
days, guidelines were developed and a process outlined to improve
communication between the BMT and ICU teams, and the teams
and the family. Background: Appropriate resource utilization is
critical with rising health care costs and the scarcity of ICU beds.
Guidelines were needed for the appropriate admission of BMT pa-
tients to the ICU.
Communication between medical teams was often fragmented.
Additionally family members often receive conflicting information
from the teams. Unclear communication makes it difficult for
patients and families to make educated decisions regarding care
options, which can result in over utilization of the ICU for non-
beneficial care. Procedure: Our BMT program had an increase
in ICU utilization, with ICU days increased from 3.3% in FY05
to 5.1% in FY06. Average BMT ICU LOS increased from 4.8
days to 11.7 days.
A multidisciplinary team met to discuss current issues, brain-
storm ideas and create guidelines based on current literature. The
following guidelines were developed:
- Guidelines for appropriate admission of BMT patients to the
ICU are based on review of recent literature and probability of
survival.
- Established daily rounds between BMT and ICU teams to discuss
patients in the ICU and enhance communication.
- The BMT and ICU teammeet with the patient or family every 48
hours during ICU stay to clarify goals of care.
- BMT ICU monitoring tool developed to monitor adherence to
guidelines.
- All BMT patients sent to ICU are reviewed at the monthly BMT
meetings.
- Created a BMT Advanced Care Planning addendum to educate
patients and families and create a forum for discussion and goal
planning with their MD.
Results: To date, all but one of the 13 BMT patients transfered to
the ICU met the criteria. The BMT and ICU teams have rounded
daily and discussed the plan for all BMT patients in the ICU. In ad-
dition the teams have met with families every 3–4 days. As a result,
we have decreased BMT ICU days to 3.4% and the ICU average
LOS down to 8.1 days.
The project has resulted in guidelines for appropriate admissions
of BMT patients to the ICU. Appropriate utilization of ICU beds
for BMT patients results in better resource utilization and avoiding
futile care. The daily team rounds and family meetings team re-
sulted in clarity of information and communication to patients
and family, enabling families to make educated decisions.465
PRIORITY CONCERNS OF PATIENTS RECEIVING AUTOLOGOUS OR ALLO-
GENEIC STEM CELL TRANSPLANTS AT THE SEATTLE CANCER CARE AL-
LIANCE
Klein, C.1, Berry, D.L.1,2, Fann, J.1, Halpenny, B.2, Lober, W.2,
Wolpin, S.2, Bush, N.3. 1Seattle Cancer Care Alliance, Seattle, WA;
2University of Washington, Seattle, WA; 3Fred Hutchinson Cancer Re-
search Center, Seattle, WA.
Purpose: In a focused history, transplant clinicians may not ad-
dress the issues perceived to be most important to patients. Studies
indicate that while oncologists are attentive to adverse symptoms,
communication tends to be clinician-oriented with interruptions
and closed-ended questions. The use of touchscreen computers
by stem cell transplant (SCT) patients to report symptom and qual-
ity of life (QOL) measures has been investigated at the SCCA. The
purpose of this analysis was to identify priority concerns reported at
the time of nurse teaching (T1) and after transplant (T2), usinga self-report assessment program for cancer (ESRA-C). Methods:
228 SCT patients included in this analysis completed ESRA-C at
T1 andT2 before their clinic visits. The ESRA-C includes validated
questionnaires to assess symptoms and QOL and an open-ended
text field with the following instructions: ‘‘Please type in the two
most important concerns or issues that we should address first
with you and/or anything else youwant to tell us about.’’ The results
were content analyzed by grouping the 139 allogeneic (allo) and 89
autologous (auto) patients and identifying concerns and symptom
categories and commonalities in the written text responses.
Results: Patient characteristics included 57% men and 77% with
post-secondary education. Free text entries were more frequent at
T1. Four common global concerns were reported at T1: financial,
survival, QOL, family/caregiver issues and one symptom, depres-
sion. The two areas of highest concern were 1) financial, greater
in the auto group (13.5% vs 3.5%); and 2) survival, more common
in the allo group (13.0% vs 7.9%). Eight of the common symptoms/
side effects were categorized: fatigue, complications of graft versus
host, diarrhea, nausea, appetite loss and infection. The symptoms,
as opposed to global concerns, were reported as priority concerns
most often atT2.Conclusions:Computerized assessment is a novel
way for patients to report a spectrum of symptoms and quality of life
status, and also what is most important for that individual. Financial
concerns are not typically addressed by clinicians, particularly when
attempting to teach patients and prepare them for transplant. This
particular concern could block the patient’s ability to process and
retain information about treatment and side effects. Priority con-
cerns shifted in both groups from global concerns at T1 to symptom
concerns at T2. This shift has implications for patient education.466
DEFINING THE SYMPTOM BURDEN OF CHRONIC GRAFT VERSUS HOST
DISEASE
Williams, L.A.1, Couriel, D.R.2, Neumann, J.L.3, Whisenant, M.S.4,
Galbizo, E.O.5, Cleeland, C.S.1. 1The University of Texas MDAnderson
Cancer Center, Houston, TX; 2Sarah Cannon Cancer Center and Ten-
nessee Oncology, Nashville, TN; 3The University of Texas MD Anderson
Cancer Center, Houston, TX; 4University of Utah, Salt Lake City, UT;
5The University of Texas MD Anderson Cancer Center, Houston, TX.
Significance: Chronic graft-versus-host disease (cGVHD) is an
autoimmune-like reaction occurring after allogeneic hematopoietic
stem cell transplantation (HSCT). cGVHD causes debilitating
symptoms for patients who have been cured of underlying malig-
nancies. Oncology nursing aims to decrease the burden of symp-
toms for patients and families. Problem and Purpose: There is
scant literature addressing the symptom burden of cGVHD. The
major barrier to good symptom management is inadequate assess-
ment. The specific aims of this study are to: 1) describe the symptom
experience of cGVHD; and 2) establish the content domain for an
instrument to measure the symptom burden of cGVHD.Theoret-
ical/Scientific Framework: The framework for this study is the
concept of symptom burden. Symptom burden is the combined im-
pact of all symptoms on one’s ability to function as one did prior to
onset of disease and therapy. Methods and Analysis: This was
a qualitative, cross-sectional study. The study sample included 20
adults with active cGVHD at a comprehensive cancer center in
the southern United States. Participants described their experience
of having cGVHD in single audiotaped dialogues. Using an explor-
atory descriptive method, the researcher analyzed transcripts of the
dialogues and developed themes of the cGVHD symptom experi-
ence. To ensure accuracy, identification of themes by the researcher
was reviewed and confirmed by 3 other researchers experienced in
qualitative analysis, oncology nursing, symptom assessment, and
HSCT. The themes were used to construct a unified description
of the symptom burden of cGVHD. Findings and Implications:
The symptom burden of cGVHD is multiple symptoms that inter-
fere with daily activities and require self-care management. Symp-
tom burden increases the longer the symptoms persist and the
more uncertain the occurrence of the symptoms and the outcome
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strument to measure the symptom burden of cGVHD should in-
clude questions about the severity of numerous symptoms and
how those symptoms have interfered with normal functioning.
Symptom burden should be measured longitudinally to capture
changes in symptom burden over time. Clinicians caring for pa-
tients with cGVHD should reduce uncertainty as much as possible
by offering clear explanations and should support patients in appro-
priate efforts at self-care to relieve symptoms.PHARMACY467
CLONAZEPAM PLUS LEVETIRACETAM (CL) FOR THE PREVENTION OF
BUSULFAN-INDUCED SEIZURES: A SINGLE CENTER EXPERIENCE
Bubalo, J.S.1, Kovascovics, T.J.1, Meyers, G.1, Mauro, M.1, Epner, E.1,
Hayes-Lattin, B.1, Deininger, M.1, Curtin, P.T.2, Leis, J.F.3,
Maziarz, R.T.1. 1Oregon Health & Science University Hospital, Port-
land, OR; 2University of California San Diego, San Diego, CA; 3Mayo
Clinic, Phoenix, AZ.
High dose busulfan (.1 mg/kg) used in hematopoietic stem cell
transplant (HSCT) conditioning regimens is associated with a de-
crease in seizure threshold which can result in partial or generalized
seizures in up to 10% of people without a previous seizure history.
Phenytoin is the most frequently used agent to prevent seizures.
Though this is an effective therapy, the frequent side effects and sig-
nificant risk for drug interactions from phenytoin make it a subopti-
mal agent for this purpose. Also there is no preferred anti-seizure
prophylaxis for phenytoin allergic or intolerant patients. A retro-
spective review was performed of a single center experience using
CL in 46 consecutive patients receiving a variety of inpatient and
outpatient busulfan-containing regimens to assess it for side effects
and efficacy. The patients received the CL regimen over a 13month
period beginning July, 2006. Clonazepam 0.5 mg and levetiracetam
500mg where given together orally twice daily, beginning the even-
ing before busulfan therapy initiated until discontinuation on the
morning after the final busulfan dose was given. All patients were
adults, 20 female/26 male, aged 22–75 years, (mean 52, median 56
y/o), weight 54–113 kg (Mean and median 82 kg), with no prior his-
tory of seizures. They received HSCT conditioning regimens con-
taining oral (PO) busulfan 1 mg/kg/dose  12–16 doses, or
intravenous (IV) busulfan 3.2 mg/kg/day  1–3 days as part of the
following regimens: 5 - busulfan (12 mg/kg PO)/melphalan(100
mg/m2)/thiotepa 500 mg/m2), 4 - busulfan (9.6 mg/kg IV)/melpha-
lan(100 mg/m2)/thiotepa 500 mg/m2), 20 - busulfan (16 mg/kg)
PO/cyclophosphamide (120 mg/m2), and 16 - busulfan 3.2 mg/kg
IV/fludarabine (120 mg/m2/TBI (200 cGy). The regimen was com-
pletely successful with no patients experiencing any type of seizure
within 48 hours of their last dose of busulfan. Side effects were mild:
2 patients reporting mild sedation and 1 patient had their levetira-
cetam dose reduced to 250 mg twice daily for confusion. When
compared to the prior 104 patients receiving the same variety of
conditioning regimens with phenytoin anti-seizure prophylaxis,
fewer side effects were seen, with equal anti-seizure benefits and
a limited risk for drug interactions using the CL regimen. The
CL regimen is now the preferred therapy for busulfan seizure pro-
phylaxis for the transplant center.468
METHOTREXATE AND PIPERACILLIN/TAZOBACTAM VERSUS METHO-
TREXATE AND CEFTAZIDIME: A LOOK AT TIME TO ENGRAFTMENT
AND SIDE EFFECT PROFILE DIFFERENCES IN HEMATOPOIETIC STEM
CELL TRANSPLANT PATIENTS
Hoffmann, P.D., Haight, A.E. Children’s Healthcare of Atlanta, At-
lanta, GA.
Many HSCT patients receive methotrexate for GVHD prophy-
laxis. Commonly, methotrexate is given on days 11, 13, 16, and
variably 111. Most patients develop fever during this time period
and empiric antibiotics are started.In June 2006, our institution’s SOP changed the empiric antibi-
otic for fever from ceftazidime to piperacillin/tazobactam. Penicil-
lin derivatives interact with antineoplastic doses of methotrexate by
competing for renal tubular binding sites. Methotrexate toxicity
may include severe mucositis, marrow suppression, renal dysfunc-
tion, and hepatotoxicity. Smaller doses of methotrexate, like those
used for GVHD prophylaxis, have not been investigated. We eval-
uated side effects in patients who may have prolonged methotrexate
exposure caused by piperacillin/tazobactam co-administration.
We examined 36 patients over two years who receivedmethotrex-
ate for GVHD prophylaxis, comparing patients who received ceph-
alosporins with those receiving piperacillin/tazobactam. The
cephalosporin group included 23 patients (14 females, 9 males),
from July 1, 2005 to June 30, 2006. Average time to engraftment
(the first of three consecutive days with ANC . 500) was 18.25
(range 12–22) days for matched unrelated donor (MUD) trans-
plants, 11.9 (9–20) for matched sibling (MS) transplants, and
16.33 (14–19) for mismatched related transplants; overall average
for this group was 16.04 days to engraft. The piperacillin/tazobac-
tam group included a total of 13 patients (11 males, 2 females), from
July 1, 2006 to June 30, 2007. MUD transplants averaged 20.2 (16–
23) days, and MS transplants 17.4 (15–22); overall average was 18.7
days to engraft. Average days antibiotics overlapped methotrexate
was 6.17 and 5.46 for cephalosporin and piperacillin/tazobactam
groups, respectively. No significant differences in transaminases,
bilirubin, and serum creatinine were noted.
In summary, only a difference in time to engraftment was found,
with the piperacillin/tazobactam group taking 2.66 days longer.
This study is limited by small sample size and potential confounding
variables. Mucositis severity could not be compared in this retro-
spective study, but would be of interest for future studies. Based
on this small, retrospective single institution study, we conclude
that a major interaction between small doses of methotrexate and
piperacillin/tazobactam is not seen.469
HIGH RATE OF REVACCINATION IN ALLOGENEIC AND EARLY AUTOLO-
GOUS STEM CELL TRANSPLANTATION—RESULTS OF A SINGLE CENTER
COMPLIANCE TRACKING SURVEY
West, K., Brown, K., Paplham, P., Privitere, L., Syta, M.,
Battiwalla, M., Smiley, S., McCarthy, P.L. Roswell Park Cancer Insti-
tute, Buffalo, NY.
Background:Hematopoietic stem cell transplants (HSCT) have
increased over the past 25 years. With improving HSCT outcomes,
the number of long-term survivors has grown. HSCT recipients
lose their memory immune response against common vaccine-pre-
ventable infections and suffer from life-threatening late infectious
complications. Revaccination is an important strategy for reducing
the risk of preventable infections after HSCT. Materials and
Methods: After the implementation of an annual post transplant
clinic, compliance with revaccination recommendations of the In-
fectious DiseaseWorking Party of the EBMT (BMT 2005) was an-
alyzed. Initially letters were sent to patients greater than 1 year post
transplant inviting them to visit the clinic. The goal of the annual
clinic was to educate HSCT recipients, identify complications,
and recommend therapy for long-term post-transplant issues. Pa-
tients were encouraged to bring their immunization records to their
appointments. Data were collected from January 2006 until August
2007 utilizing patient histories and computer data base documenta-
tion tools for the clinic. Schedules were generated based on the rec-
ommendations of the Infectious Diseases Working Party of the
EBMT. Results: 42 subjects, 27 autologous and 15 allogeneic, at-
tended annual clinic during this time period. 27 patients had initi-
ated the recommended vaccination schedule and/or elected to
start or continue the re-immunization schedule after attending
the clinic. Fifteen patients declined vaccinations (11 autos and 4 al-
los) for various reasons including time out from transplant (median
10 years), 1 completed recommended series, 1 due to immunosup-
pressive therapy, and 1 with history of adverse reaction to vaccine
excipients. Patients declining full revaccination were encouraged
to maintain standard revaccinations such as yearly influenza shots
and ten year diphtheria/tetanus boosters. There were no toxicities
associated with revaccination. Conclusion: Education and
